Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis

Joseph A. Chacko, Paolo Strati, Paul W. Stout, Robert L. Archer, Brad P. Baltz, Joseph G. Chacko

Research output: Contribution to journalLetterpeer-review

4 Scopus citations

Abstract

Background: There are multiple case reports in the literature describing an association between fingolimod and cutaneous neoplasms. Objective: Investigate and report a case of a primary mediastinal large B-cell lymphoma in a patient on fingolimod for Relapsing-Remitting Multiple Sclerosis (RRMS). Methods: Case Report. Results: The patient developed a primary mediastinal large B-cell lymphoma after seven years of treatment with fingolimod. The patient is currently in complete remission after cessation of treatment, surgical resection, chemotherapy, and radiation therapy. Conclusion: This case report highlights the first primary mediastinal large B-cell lymphoma associated with fingolimod treatment. It should be considered a rare, but potential adverse effect of fingolimod.

Original languageEnglish (US)
Article number102776
JournalMultiple Sclerosis and Related Disorders
Volume49
DOIs
StatePublished - Apr 2021

Keywords

  • CD30
  • Fingolimod
  • Lymphoma
  • Multiple sclerosis
  • Primary mediastinal large B-cell lymphoma

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis'. Together they form a unique fingerprint.

Cite this